Infantile hemangioma with cleft lip in a term female infant born to a mother with pregnancy-induced hypertension
DOI:
https://doi.org/10.18203/2349-3291.ijcp20252975Keywords:
Infantile hemangioma, Ulceration, Cleft lip, Pregnancy-induced hypertension, Atenolol, Beta-blockers, Vascular tumors, PHACE syndromeAbstract
Infantile hemangioma (IH) is the most common benign vascular tumor in infancy, affecting approximately 4–10% of neonates, with a higher prevalence in females and premature infants. Although typically self-limiting, IHs can lead to complications such as ulceration, disfigurement, or functional impairment—particularly when located near vital anatomical structures. This case reports a case of a 40-day-old term female infant presenting with multiple reddish raised lesions over the upper lip and right shoulder, clinically diagnosed as infantile hemangiomas. The infant was born to a mother with pregnancy-induced hypertension (PIH), managed antenatally with labetalol. Examination revealed a central ulcerated lesion on the upper lip and a smaller non-ulcerated lesion over the right shoulder. A congenital cleft lip was also noted, without cleft palate involvement. Systemic evaluations including abdominal and cranial ultrasound, echocardiography, and 12-lead electrocardiogram (ECG) were within normal limits. Topical becaplermin 0.01% gel was applied twice daily for two weeks to promote ulcer healing, followed by oral atenolol at a dose of 0.25 mg/kg/dose twice daily. The treatment was well tolerated, with no adverse effects. Significant regression of both lesions was observed over the following weeks. Although PHACE syndrome was initially suspected due to facial involvement and cleft lip, it was ruled out based on normal neuroimaging and cardiac assessments. This case highlights the successful use of atenolol as a safe and effective alternative to propranolol in the treatment of complicated IHs. Early diagnosis, comprehensive evaluation to exclude syndromic associations, and timely therapy are essential to avoid complications and ensure favorable outcomes.
Metrics
References
Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-51. DOI: https://doi.org/10.1056/NEJMc0708819
Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128-40. DOI: https://doi.org/10.1542/peds.2012-1691
Roversi FM, Gontijo B, Silva CMR. Oral propranolol for infantile hemangioma: A systematic review. An Bras Dermatol. 2018;93(3):356-60.
Haggstrom AN, Lammer EJ, Schneider RA, Marcucio R, Frieden IJ. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics. 2006;117(3):698-703. DOI: https://doi.org/10.1542/peds.2005-1092
Hoornweg MJ, Smeulders MJ, Ubbink DT, van der Horst CM. The prevalence and risk factors of infantile haemangiomas: A case-control study in the Dutch population. Paediatr Perinat Epidemiol. 2012;26(2):156-62. DOI: https://doi.org/10.1111/j.1365-3016.2011.01214.x
Metry D, Heyer G, Hess C. Consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics. 2009;124(5):1447-56. DOI: https://doi.org/10.1542/peds.2009-0082
Pandey A, Gangopadhyay AN, Sharma SP, Kumar V. Atenolol in infantile hemangioma: an emerging therapeutic option. J Indian Assoc Pediatr Surg. 2021;26(1):26-30.
Baselga E, Roe E, Coulie J. Atenolol vs propranolol for the treatment of infantile hemangiomas: a multicenter, randomized, open-label trial. JAMA Dermatol. 2021;157(5):548-54.
Pope E, Krafchik BR, Macarthur C. Becaplermin gel in the treatment of ulcerated hemangiomas: a randomized, placebo-controlled trial. Arch Dermatol. 2007;143(9):1147-51.
Zvulunov A, McCuaig C, Frieden IJ. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2011;127(3):e718-26.